Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  H. Lundbeck    LUN   DK0010287234

H. LUNDBECK (LUN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
09/18/2018 09/19/2018 09/20/2018 09/21/2018 09/24/2018 Date
381.9(c) 383.1(c) 384.1(c) 381.2(c) 387.4 Last
480 487 369 919 181 874 331 698 213 939 Volume
-2.03% +0.31% +0.26% -0.76% +1.63% Change
More quotes
Financials (DKK)
Sales 2018 17 991 M
EBIT 2018 5 549 M
Net income 2018 3 858 M
Finance 2018 5 659 M
Yield 2018 3,16%
Sales 2019 17 050 M
EBIT 2019 5 114 M
Net income 2019 3 564 M
Finance 2019 7 354 M
Yield 2019 3,22%
P/E ratio 2018 19,80
P/E ratio 2019 21,27
EV / Sales2018 3,90x
EV / Sales2019 4,02x
Capitalization 75 896 M
More Financials
Company
H. Lundbeck A/S engages in the research, development, and market of pharmaceutical products for the treatment of psychiatric and neurological disorders.It operates through the following geographical segments: Europe, the Unites States of America, and International Markets.Its product portfolio... 
Sector
Pharmaceuticals
Calendar
11/07Earnings Release
More about the company
Surperformance© ratings of H. Lundbeck
Trading Rating : Investor Rating :
More Ratings
Latest news on H. LUNDBECK
09/24H LUNDBECK : Survey Findings Highlight the Burden of Neurogenic Orthostatic Hypo..
BU
08/10H LUNDBECK : Lundbeck Brings Potential New Biologic Treatment of Parkinson's Dis..
AQ
08/09H LUNDBECK : Patent Issued for Liquid Formulations Of Salts Of 1--Piperazine (US..
AQ
08/08H LUNDBECK : Lundbeck realized 14% growth in revenue (local currencies) and 83% ..
AQ
08/08H. LUNDBECK : Half-year results
CO
08/08H. LUNDBECK : Slide show half-year results
CO
08/02H LUNDBECK : Patent Issued for Quinazolin-THF-Amines As PDE1 Inhibitors (USPTO 1..
AQ
07/19HANSA MEDICAL : Interim report April - June 2018
AQ
07/02H LUNDBECK : Dr. Deborah Dunsire named new President and CEO of Lundbeck
AQ
06/28H LUNDBECK : Lundbeck starts clinical development of potential new treatment of ..
AQ
More news
Sector news : Pharmaceuticals - NEC
09/24ASTRAZENECA : EU Grants Marketing Authorization to AstraZeneca's Imfinzi
DJ
09/24ALEXION PHARMACEUTICALS : Soliris Meets Main Endpoint in Central Nervous System ..
DJ
09/24ASTRAZENECA : Mixed Results from Farxiga Trial
DJ
09/24SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
09/24As China builds biotech sector, cash floods U.S. startups
RE
More sector news : Pharmaceuticals - NEC
Latest Tweets
09/12“Patients are the center of everything we do; they drive us forward and keep ..
4
09/12Peter Anastasiou of is here discussing the research and development happenin..
1
09/11Peter Anastasiou of is here discussing the research and development happenin..
2
08/13Jefferies Financial Group Lowers H. Lundbeck A/S- Q3 2018 Earnings Estimates .. 
07/06Chutes & Ladders—Ex-Millennium chief Deborah Dunsire named CEO of Lundbec.. 
More tweets
Qtime:37
News from SeekingAlpha
09/14Key events next week - healthcare 
08/31FDA tentatively OKs Aquestive's Sympazan for severe type of childhood epileps.. 
08/11H. Lundbeck A/S (HLUKF) CEO Anders Götzsche on Q2 2018 Results - Earnings Cal.. 
08/09After A Wild Party, Lundbeck Wakes To A Nasty Hangover 
08/08H. Lundbeck A/S ADR 2018 Q2 - Results - Earnings Call Slides 
Chart H. LUNDBECK
Duration : Period :
H. Lundbeck Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends H. LUNDBECK
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 17
Average target price 348  DKK
Spread / Average Target -8,8%
EPS Revisions
Managers
NameTitle
Deborah L. Dunsire President & Chief Executive Officer
Lars Søren Rasmussen Chairman
Anders Götzsche Chief Financial Officer & Executive Vice President
Lars Bang Executive VP-Supply Operations & Engineering
Anders Gersel Pedersen Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
H. LUNDBECK21.02%12 046
JOHNSON & JOHNSON2.26%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
ROCHE HOLDING LTD.-4.60%211 501
MERCK AND COMPANY26.36%189 092